Results from the randomised, blinded study 201316 showed that umeclidinium 62.5mcg once daily achieved a statistically significant improvement in lung function measured by trough forced expiratory volume in
Until today’s orphan drug approval, no specific coagulation factor replacement therapy was available for patients with hereditary Factor X deficiency. In healthy individuals, the Factor X protein activates
Praxbind is indicated for patients treated with Pradaxa® (dabigatran etexilate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or
The company has received an initial investment of $10 million, with an additional $15 million due upon the achievement of certain milestones. Proceeds from the Series B financing
It will join targeted Pulse Electro Magnetic Field therapy (tPEMF) and closed-loop Transcranial Electrical Stimulation (cl-TES) as one of Rio Grande Neurosciences’ core technologies. Despite undergoing treatment with
The investment will accelerate Science 37’s development and rollout of its new operating model, which solves some of the greatest inefficiencies in conducting clinical trials. Science 37 co-founder
The partnership will seek to apply Riverside Research’s patented, quantitative, tissue-characterization algorithms to the ExactVu™ high-resolution micro-ultrasound platform to develop new capabilities in the system’s ability to detect
The summit aims to address the vital role of scientific research in the improvement and sustainable development of the African population health, with specific emphasis on how to
Their findings, published in Neurosurgery, lend hope to patients around the world with neurological conditions that are difficult to treat due to a barrier mechanism that prevents approximately
This phase IIa study is a randomized, open-label, three-arm study of AL-335, a nucleotide-based HCV NS5B polymerase inhibitor, odalasvir, an HCV NS5A inhibitor and simeprevir, an HCV NS3/4A
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.